Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1]

Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]: 35 )

References

  1. ^ Fresenius
  2. ^ ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
  3. ^ "2009 Consolidated Financial Statements and Management Report of Fresenius SE" (PDF). Archived from the original (PDF) on 2016-03-31. Retrieved 2016-03-20.